Dapagliflozin vs. Saxagliptin: Durability of Glycemic Control
Dec 16, 2019
Editor: Steve Freed, R.PH., CDE
Author: Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has been established to have higher glycemic efficacy, reduction in weight, and reduction in systolic blood pressure than the dipeptidyl peptidase-4 (DPP4) inhibitor saxagliptin. Previous studies have not compared both medications in head-to-head trials in the aspects of the durability of control of HbA1c, fasting plasma glucose, systolic blood pressure, and body weight. This study aimed to assess the durability of HbA1c lowering by reviewing three randomized trials of dapagliflozin vs. saxagliptin in patients with type 2 diabetes over short- and long-term follow-up periods....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.